Cullinan Oncology – Cancer Research
Nadim Ahmed, President and CEO of Cullinan Oncology, a clinical-stage biotechnology company developing a diversified pipeline of potential first - and best-in-class targeted therapies for patients with cancer, discusses his perspective on the future of the oncology treatment landscape, as well as what Cullinan Oncology is specifically doing for patients with unmet needs and to advance its diverse portfolio of differentiated oncology assets.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Nadim has more than twenty-five years of leadership experience in oncology across a range of development and commercialization roles, including recently at Bristol Myers Squibb (BMS), where he served as President, Hematology and at Celgene Corporation (Celgene) where he served as President, Global Hematology & Oncology through its acquisition by BMS. As President, Hematology at BMS, Nadim oversaw multiple product launches and participated as a member of the company’s Leadership Team. Prior to BMS, Nadim served in leadership roles at Celgene across both development and commercialization functions. During this time at Celgene, he successfully launched multiple cancer medicines, including Pomalyst ®, Abraxane ® and several key indications for Revlimid ®. Nadim has worked with various treatment modalities, including small molecules, biologics and cell therapy in hematology and solid tumors. Nadim holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.
Nadim currently serves on the Board of Directors for Family Promise, a national non-profit organization helping homeless families.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
